An anonymous director reports
NYMOX ANNOUNCES $2 MILLION PRIVATE PLACEMENT
Nymox Pharmaceutical Corp. has arranged an investment of $2-million (U.S.) for two million shares at the price of $1 (U.S.) per share with
500,000 warrants priced at $2 (U.S.). The investment comes from James Robinson, a long-term shareholder of Nymox
and a distinguished member of the Board of Directors of the Company. The funds will be used for general corporate
purposes. The investment will close in the upcoming days after the customary formalities are completed.
About NYMOX
Nymox is in the process of submitting applications for the approval to market the Company's first in class drug
NYMOZARFEX to treat the symptoms of benign prostatic hyperplasia (BPH). BPH is one of the most common
conditions affecting middle aged and elderly men throughout the world. BPH can be devastating to men who suffer
from the condition. Current treatments are associated with numerous intolerable side effects including sexual
problems, such as impotence and retrograde ejaculation. Medications for BPH have been associated with prostate
cancer, depression, gynecomastia and other adverse effects. The majority of men stop taking the available
medications due to these and other problems. Surgery is often needed for advanced BPH. Surgery is usually
effective but it is not without risks, the discomforts of surgery, and BPH surgery has side effects such as permanent
retrograde ejaculation for many patients.
Nymox recently reported 10-year follow-up new data on all available patients from its U.S. clinical trial of
NYMOZARFEX (TM) for the treatment of low grade localized prostate cancer. The available long-term data newly
assessed, confirmed that all available data shows that the NYMOZARFEX (TM) treatment had important
and statistically significant benefit for reducing the long-term progression of these prostate cancers.
About NYMOZARFEX (TM) (Fexapotide)
NYMOZARFEX (TM) is given in an in-office procedure that is administered in a few minutes without need of
anesthesia or analgesia. The drug has been tested in clinical trials involving overall more than 1750 patients with
over 1600 injections administered including over 1200 NYMOZARFEX (TM) administrations. NYMOZARFEX
(TM) has led to significant long-term improvements and has shown an excellent safety profile without the side effects
normally associated with existing BPH treatments.
We seek Safe Harbor.
© 2024 Canjex Publishing Ltd. All rights reserved.